CSL
CSL.ASXHealth Care
Development, manufacturing and marketing of pharmaceutical and diagnostic products, cell culture media and human plasma fractions.
Market Data
$97.120
-0.0%$46.7B
24.3x
$4.022
4.37%
-0.5%
Latest Earnings
CSL Half Year Results Announcement
11 February 2026
CSL reported disappointing half-year results with underlying NPATA down 7% to US$1.9 billion, heavily impacted by government policy changes, restructuring costs and asset impairments totaling ~$1.1 billion. The company maintains FY26 guidance of 2-3% revenue growth and 4-7% NPATA growth, with management expressing confidence in a stronger second half driven by immunoglobulin, albumin and newly launched products. Key points: Strong cash flow of $1.3 billion enabled expansion of share buyback from US$500m to US$750m; Transformation program achieving 60% of targeted FY26 cost savings with $500-550m annual pre-tax savings expected by FY28; CSL Vifor revenue up 12% driven by nephrology growth
Recent Announcements
CSL Half Year Results Investor Presentation
CSL delivered a challenging half-year result with revenue down 4% to $8.3B and NPATA declining 7% to $1.9B, impacted by government policy changes and restructuring costs. Despite this, the company maintained FY26 guidance and expanded its share buyback to US$750M, with strong cash flow generation and a disciplined transformation program on track. Key points: Strong cash flow generation of $1.3B (+3%); Share buyback expanded from US$500M to US$750M; Transformation program on track with 60% of FY26 savings achieved
CSL Half Year Results Announcement
CSL reported disappointing half-year results with underlying NPATA down 7% to US$1.9 billion, heavily impacted by government policy changes, restructuring costs and asset impairments totaling ~$1.1 billion. The company maintains FY26 guidance of 2-3% revenue growth and 4-7% NPATA growth, with management expressing confidence in a stronger second half driven by immunoglobulin, albumin and newly launched products. Key points: Strong cash flow of $1.3 billion enabled expansion of share buyback from US$500m to US$750m; Transformation program achieving 60% of targeted FY26 cost savings with $500-550m annual pre-tax savings expected by FY28; CSL Vifor revenue up 12% driven by nephrology growth
Earnings Release - 10 February 2026
Upcoming earnings release expected 10 February 2026 (from Yahoo Finance (confirmed))
Get real-time alerts for CSL
Receive AI-powered earnings summaries and instant notifications when CSL releases results.
Register Free